9 completed, 4 unknown, 2 not yet recruiting, 2 recruiting. 7 Phase 1, 7 Phase 3, 5 Phase 2, 1 Not applicable.
Follow Experimental drug: new trials by email Literature Review of Experimental drug trials Research Report on Experimental drug
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SALI-10 Probiotic to Reduce Osteoradionecrosis and Dental Toxicity Following Radiation Therapy for Head and Neck Cancer Standard of Care (SOC), Experimental drug - Head and Neck Cancer | Phase 3 | Not yet recruiting | University Health Network, Toronto | 288 | 2026-11-01 | 2026-10-20 |
| Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC Experimental drug - Locally Advanced Nasopharyngeal Carcinoma | Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 58 | 2024-12-31 | 2024-12-30 |
| Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects Vamorolone, Eplerenone, Fludrocortisone - Pharmacodynamic | Phase 1 | Completed | Santhera Pharmaceuticals | 30 | 2024-06-05 | 2025-09-11 |
| Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward Amoxicillin, Amoxicillin/clavulanate - Community-acquired Pneumonia | Phase 3 | Recruiting | Nantes University Hospital | 326 | 2024-04-25 | 2026-04-08 |
| Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC Experimental drug, Control Rx - Metastatic Microsatellite-stable Colorectal Cancer | Phase 3 | Recruiting | Sun Yat-sen University | 176 | 2023-03-01 | 2023-03-14 |
| Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status Experimental drug - Colorectal Cancer, Liver Metastases | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2022-10-01 | 2022-06-08 |
| A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers PRV-002, Placebo - Traumatic Brain Injury (TBI) | Phase 1 | Completed | Odyssey Group International, Inc. | 40 | 2022-02-09 | 2024-11-04 |
| NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) Placebo, Experimental drug - COVID-19 Pandemic | Phase 1 / Phase 2 | Terminated | Medesis Pharma SA | 7 | 2022-02-04 | 2023-10-26 |
| To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain. orphenadrine, acetaminophen, caffeine and diclofenac sodium, Diclofenac Sodium 50 MG, Placebo (for experimental drug) - Postural Low Back Pain, Mechanical Low Back Pain | Phase 3 | Unknown | Ache Laboratorios Farmaceuticos S.A. | 110 | 2021-01-01 | 2020-09-03 |
| IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. Experimental drug - SARS Virus | Phase 2 | Unknown | Versailles Hospital | 99 | 2020-09-01 | 2020-08-07 |
| FEcal Microbiota Transplantation Experimental drug - Depression in Schizophrenia | Not applicable | Unknown | Assistance Publique Hopitaux De Marseille | 3088 | 2019-12-01 | 2019-06-28 |
| Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1) YYD601 20mg, Nexium tab 20mg - GERD | Phase 1 | Completed | Yooyoung Pharmaceutical Co., Ltd. | 28 | 2019-07-08 | 2021-05-11 |
| Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity Inditreat, Experimental drug - Metastatic Pancreatic Cancer | Completed | Vejle Hospital | 12 | 2019-02-25 | 2023-05-01 | |
| Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment PF-05221304 - Hepatic Impairment | Phase 1 | Completed | Pfizer | 24 | 2017-12-19 | 2019-08-08 |
| Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease DS-5565, Placebo - Fibromyalgia | Phase 3 | Completed | Daiichi Sankyo | 56 | 2015-06-26 | 2020-11-24 |
| Stannsoporfin With Light Therapy for Newborn Babies With Jaundice Phototherapy, Stannsoporfin, Placebo - Jaundice, Neonatal, Hyperbilirubinemia, Neonatal | Phase 2 | Completed | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 91 | 2013-10-16 | 2020-02-06 |
| The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects YH4808, Nexium, Amoxicillin - Healthy | Phase 1 | Completed | Yuhan Corporation | 95 | 2013-07-01 | 2013-12-03 |
| Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects Lyrica, Experimental drug, High fat meal - Healthy | Phase 1 | Completed | IlDong Pharmaceutical Co Ltd | 30 | 2012-11-01 | 2014-09-01 |
| Effectiveness of Transverse Abdominus Plane Catheter Blocks to Patient-controlled Analgesia in Laparoscopic Colon Resections 0.2% ropivacaine, Saline - Colorectal Disorders, Observation of Neuromuscular Block | Phase 3 | Withdrawn | Stamford Hospital | 2012-05-01 | 2016-12-06 |
Colorectal Neoplasms (2) · Brain Injuries, Traumatic (1) · COVID-19 (1) · Community-Acquired Pneumonia (1) · Fibromyalgia (1) · Gastroesophageal Reflux (1) · Glucosephosphate Dehydrogenase Deficiency (1) · Head and Neck Neoplasms (1) · Hyperbilirubinemia, Neonatal (1) · Jaundice, Neonatal (1) · Low Back Pain (1) · Neuralgia (1) · Pancreatic Neoplasms (1) · Renal Insufficiency, Chronic (1) · Severe Acute Respiratory Syndrome (1)
Ache Laboratorios Farmaceuticos S.A. (1) · Assistance Publique Hopitaux De Marseille (1) · Daiichi Sankyo (1) · IlDong Pharmaceutical Co Ltd (1) · InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company (1) · Medesis Pharma SA (1) · Nantes University Hospital (1) · Odyssey Group International, Inc. (1) · Pfizer (1) · Santhera Pharmaceuticals (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Stamford Hospital (1) · Sun Yat-sen University (1) · University Health Network, Toronto (1) · Vejle Hospital (1)
United States (4) · China (3) · Czechia (2) · France (2) · South Korea (2) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Denmark (1) · Germany (1) · Hungary (1) · Poland (1) · Romania (1)
Lars Henrik Jensen, MD, PhD (1) · Mauro C Junior, M.D. (1) · Morton A Scheinberg, M.D. (1)
PMID 32274381, PMID 32999432, PMID 33062627, PMID 39803609, PMID 40957504
2014 (1), 2017 (1)